RNPC3 and scleroderma: MCTD was first described in 1972 by Sharp et al. as a distinct rheumatological condition presenting with features of SLE, scleroderma and polymyositis, characterized by the presence of anti‐RNP antibodies, and showing excellent response to corticosteroids.1